Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02365896
Other study ID # TLDG vs. LADG
Secondary ID
Status Not yet recruiting
Phase N/A
First received January 23, 2015
Last updated April 24, 2015
Start date June 2015

Study information

Verified date January 2015
Source Fujian Cancer Hospital
Contact Weidong Zang, Associate chief physician
Phone 13600815361
Email fjzangwd@163.com
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

Prospective Randomized Controlled Multicenter Clinical Trial for Comparison of Safety Between Totally Laparoscopic Distal Gastrectomy(TLDG) and Laparoscopy-Assisted Distal Gastrectomy(LADG) With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric Cancer


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 176
Est. completion date
Est. primary completion date May 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- The diagnosis of gastric cancer was confirmed by pathological examination

- Preoperative staging as cT2-4aN0-3M0 according to AJCC-7th

- No accompany with another cancer

- ECOG 0-1

- ASA I-III

- Agreement

Exclusion Criteria:

- Pregnant or suckling period

- Patients with a history of preoperative chemoradiotherapy

- Patients with unable to finish D2 lymphadenectomy or R0 resection

- Laparoscopic surgery contraindications

- Serious organ disfunction

- Accompany with serious mental disease

- Continuous treatment with steroid in 1 month

- Disagreement

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
TLDG or LADG


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Fujian Cancer Hospital

References & Publications (8)

Han G, Park JY, Kim YJ. Comparison of short-term postoperative outcomes in totally laparoscopic distal gastrectomy versus laparoscopy-assisted distal gastrectomy. J Gastric Cancer. 2014 Jun;14(2):105-10. doi: 10.5230/jgc.2014.14.2.105. Epub 2014 Jun 30. Erratum in: J Gastric Cancer. 2014 Dec;14(4):284. — View Citation

Ikeda O, Sakaguchi Y, Aoki Y, Harimoto N, Taomoto J, Masuda T, Ohga T, Adachi E, Toh Y, Okamura T, Baba H. Advantages of totally laparoscopic distal gastrectomy over laparoscopically assisted distal gastrectomy for gastric cancer. Surg Endosc. 2009 Oct;23(10):2374-9. doi: 10.1007/s00464-009-0360-3. Epub 2009 Mar 5. — View Citation

Kim BS, Yook JH, Choi YB, Kim KC, Kim MG, Kim TH, Kawada H, Kim BS. Comparison of early outcomes of intracorporeal and extracorporeal gastroduodenostomy after laparoscopic distal gastrectomy for gastric cancer. J Laparoendosc Adv Surg Tech A. 2011 Jun;21(5):387-91. doi: 10.1089/lap.2010.0515. Epub 2011 May 11. — View Citation

Kim MG, Kim KC, Kim BS, Kim TH, Kim HS, Yook JH, Kim BS. A totally laparoscopic distal gastrectomy can be an effective way of performing laparoscopic gastrectomy in obese patients (body mass index=30). World J Surg. 2011 Jun;35(6):1327-32. doi: 10.1007/s00268-011-1034-6. — View Citation

Lee J, Kim D, Kim W. Comparison of laparoscopy-assisted and totally laparoscopic Billroth-II distal gastrectomy for gastric cancer. J Korean Surg Soc. 2012 Mar;82(3):135-42. doi: 10.4174/jkss.2012.82.3.135. Epub 2012 Feb 27. — View Citation

Oki E, Sakaguchi Y, Ohgaki K, Saeki H, Chinen Y, Minami K, Sakamoto Y, Toh Y, Kusumoto T, Maehara Y. Feasibility of delta-shaped anastomoses in totally laparoscopic distal gastrectomy. Eur Surg Res. 2011;47(4):205-10. doi: 10.1159/000332850. Epub 2011 Oct 13. — View Citation

Song KY, Park CH, Kang HC, Kim JJ, Park SM, Jun KH, Chin HM, Hur H. Is totally laparoscopic gastrectomy less invasive than laparoscopy-assisted gastrectomy?: prospective, multicenter study. J Gastrointest Surg. 2008 Jun;12(6):1015-21. doi: 10.1007/s11605-008-0484-0. Epub 2008 Feb 7. — View Citation

Woo J, Lee JH, Shim KN, Jung HK, Lee HM, Lee HK. Does the Difference of Invasiveness between Totally Laparoscopic Distal Gastrectomy and Laparoscopy-Assisted Distal Gastrectomy Lead to a Difference in Early Surgical Outcomes? A Prospective Randomized Trial. Ann Surg Oncol. 2015;22(6):1836-43. doi: 10.1245/s10434-014-4229-x. Epub 2014 Nov 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary postoperative early anastomotic morbidity 30 days Yes
Secondary Flatus time 7 days Yes
Secondary Quality of life estimated with EORTC QLQ-C30V3?EORTC QLQ-STO22 30 days Yes
Secondary Postoperative hospital stay 30 days Yes
Secondary Pain score 10 days Yes
Secondary Postoperative inflammation response using C-reactive protein?IL-6?WBC and so on postoperative 1,3,5,7 days 10 days Yes
Secondary Nutrition NRS-2002 and PG-SGA in 30 days 30 days Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05545436 - Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT05524974 - Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes Phase 2
Active, not recruiting NCT03192735 - Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT03961373 - Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer Phase 3
Completed NCT02192983 - A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer. N/A
Not yet recruiting NCT05610332 - Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes Phase 3
Recruiting NCT02855788 - Metronomic Chemotherapy in Advanced Gastric Cancer Phase 2
Not yet recruiting NCT06459921 - Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer Phase 2
Recruiting NCT05141747 - A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. Phase 2
Active, not recruiting NCT06277453 - Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy
Recruiting NCT05528367 - Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Phase 2
Recruiting NCT04792515 - Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer Phase 2
Active, not recruiting NCT06235164 - The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
Recruiting NCT03322969 - Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy Phase 2
Recruiting NCT02302794 - A Multicenter Clinical Trial on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery Phase 3